NCT04910230View on ClinicalTrials.gov

Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

April 2, 2020

Study Completion Date

April 2, 2020

Conditions
Covid19Lymphopenia
Interventions
DRUG

nicotinamide

In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses

Trial Locations (1)

110016

General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

Qiang Hu

OTHER

NCT04910230 - Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19 | Biotech Hunter | Biotech Hunter